What treatment would you offer for patients with metastatic NSCLC (adenocarcinoma) who are EGFR positive AND PD-L1 >50%, who fail first line EGFR therapy (and are negative for T790M mutation)?

There are many clinical trial approaches that are evaluating immunotherapy among patients with EGFR mutations. Yet, there is little data to date of large populations of patients with long lasting responses to single agent PD-1 or PD-L1 inhibitors in the setting of EGFR mutations. Outside of a clinic...